Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by MS and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of multiple sclerosis and associated cognitive changes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Able to provide informed consent.

• Aged 18 years or older at the time of enrollment.

• Able to read in either French or English.

• Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc.

⁃ are permitted)

⁃ For patients only:

• Confirmed diagnosis of MS with no signs of progressive increase in physical disability within the past six months.

• Neurological condition is medically stable during the study visit.

• Expanded Disability Status Scale (EDSS) score 0 - 8.0 at the initial visit.

Locations
Other Locations
Canada
Genge Partners, Inc.
RECRUITING
Montreal
The Neuro
RECRUITING
Montreal
Time Frame
Start Date: 2021-10-18
Estimated Completion Date: 2027-10-18
Participants
Target number of participants: 168
Treatments
EDSS 0-2.0
Confirmed diagnosis of MS with an EDSS score between 0 and 2.0.
EDSS 2.5-4.0
Confirmed diagnosis of MS with an EDSS score between 2.5 and 4.0.
EDSS 4.5-6.0
Confirmed diagnosis of MS with an EDSS score between 4.5 and 6.0.
EDSS 6.5-8.0
Confirmed diagnosis of MS with an EDSS score between 6.5 and 8.0.
Healthy Control
Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
Related Therapeutic Areas
Sponsors
Collaborators: Novartis Pharmaceuticals
Leads: Innodem Neurosciences

This content was sourced from clinicaltrials.gov

Similar Clinical Trials